Brivaracetam Oral Solution (10 mg/mL) is a prescription antiepileptic drug (anticonvulsant) used for treatment of partial-onset seizures in patients 1 month of age and older
Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management
New partnership combines Shilpa Biologicals’ development and manufacturing capabilities with SteinCares’ regional commercialization platform
Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.
Brivaracetam is the bioequivalent to Briviact Oral Solution, 10 mg/mL, of UCB
If approved, DTX401 would be the first treatment to address the disease at its root cause
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
Under the deal, Quiver will receive an undisclosed advance payment and research support
Subscribe To Our Newsletter & Stay Updated
